Zoledronic acid

Generic Name: Zoledronic acid

Brand Names: Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan

Drug Type: Small Molecule

Chemical Formula: C_₅H_₁₀N_₂O_₇P_₂

CAS Number: 118072-93-8

Unique Ingredient Identifier: 70HZ18PH24

Background: Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.

Zoledronic acid was granted FDA approval on 20 August 2001.

Indication: Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.

Associated Conditions: Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease

Associated Therapies: Bone Mineral Density

Clinical Trials

Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer

Phase 3

Conditions: Breast Cancer
Metastatic Cancer

First Posted Date: 2003-11-06

Last Posted Date: 2013-08-02

Lead Sponsor: University of Sheffield

Registration Number: NCT00072020

The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

Phase 4

Completed

Conditions: Prostate Cancer

First Posted Date: 2003-07-03

Last Posted Date: 2017-09-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT00063609

Locations: 🇺🇸
Southeastern Urological Center, PA, Tallahassee, Florida, United States
🇺🇸
Advanced Urology Med. Center, Anaheim, California, United States
🇺🇸
Grove Hill Urology, New Britain, Connecticut, United States

and more 41 locations

Bisphosphonate Treatment of Osteogenesis Imperfecta

Phase 2

Completed

Conditions: Osteogenesis Imperfecta

First Posted Date: 2003-06-30

Last Posted Date: 2017-06-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 158

Registration Number: NCT00063479

Locations: 🇺🇸
Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
UCLA - Division of Pediatric Nephrology, Los Angeles, California, United States
🇺🇸
Texas Children's Hosptial, Houston, Texas, United States

and more 6 locations

Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

First Posted Date: 2003-05-14

Last Posted Date: 2013-06-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00004928

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases

Phase 1

Completed

Conditions: Breast Cancer
Hypercalcemia of Malignancy
Metastatic Cancer
Pain

First Posted Date: 2003-05-07

Last Posted Date: 2013-05-15

Lead Sponsor: Chugai Pharmaceutical

Registration Number: NCT00060138

Locations: 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States

Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation

Phase 3

Terminated

Conditions: Osteoporosis
Prostate Cancer

Interventions: Dietary Supplement: cholecalciferol
Drug: calcium gluconate
Drug: zoledronic acid

First Posted Date: 2003-04-09

Last Posted Date: 2020-12-08

Lead Sponsor: Northwestern University

Target Recruit Count: 53

Registration Number: NCT00058188

Locations: 🇺🇸
John H. Stroger Hospital of Cook County, Chicago, Illinois, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Veterans Affairs Medical Center - Lakeside Chicago, Chicago, Illinois, United States

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2003-01-27

Last Posted Date: 2014-04-04

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00033332

Locations: 🇺🇸
Veterans Affairs Medical Center - Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
CCOP - Scott and White Hospital, Temple, Texas, United States
🇺🇸
Veterans Affairs Medical Center - Madison, Madison, Wisconsin, United States

and more 75 locations

Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer
Osteoporosis

First Posted Date: 2003-01-27

Last Posted Date: 2014-01-06

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Target Recruit Count: 120

Registration Number: NCT00049452

Locations: 🇺🇸
Carl and Dorothy Bennett Cancer Center at Stamford Hospital, Stamford, Connecticut, United States
🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
🇺🇸
Valley Hospital - Paramus, Paramus, New Jersey, United States

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions: Drug: rebimastat
Drug: zoledronic acid
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00039104

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer

Phase 3

Completed

Conditions: Osteoporosis
Breast Cancer

Interventions: Dietary Supplement: calcium salts
Dietary Supplement: cholecalciferol
Drug: zoledronic acid

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-19

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 439

Registration Number: NCT00022087

Locations: 🇺🇸
Kent General Hospital at Bayhealth Medical Center, Dover, Delaware, United States
🇺🇸
Galesburg Clinic, Galesburg, Illinois, United States
🇺🇸
Suniti Medical Corporation, Merrillville, Indiana, United States

and more 104 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy